Cargando…

The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings

BACKGROUND: This research aimed to quantify the burden of illness (BoI) in transplant eligible (TE) and transplant non-eligible (TNE) newly diagnosed multiple myeloma (NDMM) patients and their caregivers, in the first year after diagnosis: at months 0, 3, and 12. METHODS: Prospective, cross-sectiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatopoulou, Xenia, Iraqi, Wafae, Morgan, Kate, Helme, Kawitha, Spain, Victoria A, Redfearn, Jennifer, Gardiner, Brett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769147/
https://www.ncbi.nlm.nih.gov/pubmed/36569430
http://dx.doi.org/10.2147/CEOR.S367458
_version_ 1784854325424553984
author Gatopoulou, Xenia
Iraqi, Wafae
Morgan, Kate
Helme, Kawitha
Spain, Victoria A
Redfearn, Jennifer
Gardiner, Brett
author_facet Gatopoulou, Xenia
Iraqi, Wafae
Morgan, Kate
Helme, Kawitha
Spain, Victoria A
Redfearn, Jennifer
Gardiner, Brett
author_sort Gatopoulou, Xenia
collection PubMed
description BACKGROUND: This research aimed to quantify the burden of illness (BoI) in transplant eligible (TE) and transplant non-eligible (TNE) newly diagnosed multiple myeloma (NDMM) patients and their caregivers, in the first year after diagnosis: at months 0, 3, and 12. METHODS: Prospective, cross-sectional, observational NDMM study of TE and TNE patients and their caregivers from France, Germany, Italy, and Spain was conducted between May 2019 and January 2021. A structured, online questionnaire measuring disease burden, direct and costs, out-of-pocket expenses, and health-related quality of life (HRQoL) was used. Descriptive statistics were performed. RESULTS: A total of 164, 160, and 190 NDMM patients [>65 years; self-described healthy; not working; living with caregiver] answered at months 0, 3, and 12. Patients lost independence to perform daily activities; mean pain intensity rose and opioid utilization increased, more significantly among TNE patients. Overall health status and HRQoL remained stable. Median 3-month direct medical costs peaked at month 3. Specialist consultations and hospital admissions were the greatest cost amongst TE and TNE patients. Home adaptations increased out-of-pocket expenditures amongst TNE patients. Patients describing themselves as working spent a median 0 hours in the office at all time points. A total of 131, 122, and 124 caregivers answered at months 0, 3, and 12. Mean self-rated burden score rose. By month 12, half of caregivers developed stress, anxiety or depression. Most employed caregivers continued working. Productivity was low at month 0 with a trend of recovering at month 12. Caregivers of TNE compared to TE patients reported greater time burden. Caregivers’ HRQoL was stable over time. CONCLUSION: NDMM is burdensome for patients and caregivers in the first year after diagnosis. TNE patients are more dependent on caregivers and incur higher care costs than TE patients. Despite the financial, physical, and emotional burden, HRQoL remains stable possibly indicating resilience and illness adjustment amongst patients and caregivers.
format Online
Article
Text
id pubmed-9769147
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97691472022-12-22 The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings Gatopoulou, Xenia Iraqi, Wafae Morgan, Kate Helme, Kawitha Spain, Victoria A Redfearn, Jennifer Gardiner, Brett Clinicoecon Outcomes Res Original Research BACKGROUND: This research aimed to quantify the burden of illness (BoI) in transplant eligible (TE) and transplant non-eligible (TNE) newly diagnosed multiple myeloma (NDMM) patients and their caregivers, in the first year after diagnosis: at months 0, 3, and 12. METHODS: Prospective, cross-sectional, observational NDMM study of TE and TNE patients and their caregivers from France, Germany, Italy, and Spain was conducted between May 2019 and January 2021. A structured, online questionnaire measuring disease burden, direct and costs, out-of-pocket expenses, and health-related quality of life (HRQoL) was used. Descriptive statistics were performed. RESULTS: A total of 164, 160, and 190 NDMM patients [>65 years; self-described healthy; not working; living with caregiver] answered at months 0, 3, and 12. Patients lost independence to perform daily activities; mean pain intensity rose and opioid utilization increased, more significantly among TNE patients. Overall health status and HRQoL remained stable. Median 3-month direct medical costs peaked at month 3. Specialist consultations and hospital admissions were the greatest cost amongst TE and TNE patients. Home adaptations increased out-of-pocket expenditures amongst TNE patients. Patients describing themselves as working spent a median 0 hours in the office at all time points. A total of 131, 122, and 124 caregivers answered at months 0, 3, and 12. Mean self-rated burden score rose. By month 12, half of caregivers developed stress, anxiety or depression. Most employed caregivers continued working. Productivity was low at month 0 with a trend of recovering at month 12. Caregivers of TNE compared to TE patients reported greater time burden. Caregivers’ HRQoL was stable over time. CONCLUSION: NDMM is burdensome for patients and caregivers in the first year after diagnosis. TNE patients are more dependent on caregivers and incur higher care costs than TE patients. Despite the financial, physical, and emotional burden, HRQoL remains stable possibly indicating resilience and illness adjustment amongst patients and caregivers. Dove 2022-12-17 /pmc/articles/PMC9769147/ /pubmed/36569430 http://dx.doi.org/10.2147/CEOR.S367458 Text en © 2022 Gatopoulou et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gatopoulou, Xenia
Iraqi, Wafae
Morgan, Kate
Helme, Kawitha
Spain, Victoria A
Redfearn, Jennifer
Gardiner, Brett
The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings
title The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings
title_full The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings
title_fullStr The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings
title_full_unstemmed The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings
title_short The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings
title_sort burden of a multiple myeloma diagnosis on patients and caregivers in the first year: western european findings
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769147/
https://www.ncbi.nlm.nih.gov/pubmed/36569430
http://dx.doi.org/10.2147/CEOR.S367458
work_keys_str_mv AT gatopoulouxenia theburdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT iraqiwafae theburdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT morgankate theburdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT helmekawitha theburdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT spainvictoriaa theburdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT redfearnjennifer theburdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT gardinerbrett theburdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT gatopoulouxenia burdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT iraqiwafae burdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT morgankate burdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT helmekawitha burdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT spainvictoriaa burdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT redfearnjennifer burdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings
AT gardinerbrett burdenofamultiplemyelomadiagnosisonpatientsandcaregiversinthefirstyearwesterneuropeanfindings